| HOME >> MEDICINE >> TECHNOLOGY |
Table 56: China - Roche's China-based M&A activities, 1995-2010 193
Table 57: China - Shandong Qilu Pharma's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 194
Table 58: China - Shandong Qilu Pharma's sales, R&D and manufacturing infrastructure data compared with the top 2 domestic companies in China, 2010 195
Table 59: China - Merck & Co.'s top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 197
Table 60: China - Merck & Co.'s sales, R&D and manufacturing infrastructure data compared with other top 8 multinational companies in China, 2010 199
Table 61: China - Jiangsu Yangzijiang Pharma's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 202
Table 62: China - Jiangsu Yangzijiang Pharma's sales, R&D and manufacturing data compared with the top 2 domestic companies, 2010 203
Table 63: China - Novartis's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 205
Table 64: China - Novartis drugs recently listed on the NRDL, 2009 206
Table 65: China - Novartis's sales, R&D and manufacturing infrastructure data compared with other top 8 multinational companies in China, 2010 207
Table 66: China - Novartis's China-based M&A activities, 2008-2010 210
Table 67: China - GlaxoSmithKline's top 10 selling drugs ($m) and their NRDL status (China and Hong Kong), 2010 211
Table 68: China - GlaxoSmithKline's sales, R&D and manufacturing infrastructure data compared with other top 8 multinational companies in China, 2010 212
Table 69: China - GlaxoSmithKline's China-based M&A activities, 2008-2010 215
Table 70: Currency exchange rates, 2010 239
Table 71: ATC (anatomical therapeutic chemical) classification codes assigned to a given therapy area within the prescription pharmaceutical market 240
List of Figures
'/>"/>| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |